# Anext

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anext

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.anextcell.com
- Latest round: Series A (Dec 14, 2024)
- Investors on record: 2

## About

Founded in 2013 in Shanghai, China, Anext operates as a biotechnology company that focuses on the development of anti-aging and anti-aging stem cell therapy products. It was recognized as the National High-tech Enterprise. The company has applied for 33 patents, with 16 software copyrights. Its clinical-grade mesenchymal stem cell exosomes were approved by the FDA. In December 2024, Anext closed a series A funding.

The company is mainly engaged in the research and development of anti-aging and anti-aging stem cell therapy products. The company has mastered technologies such as the exosome cell repair drug ANEXT Smart EX and the exosome drug delivery carrier ANEXT Super Delivery. The main product is clinical-grade mesenchymal stem cell exosomes. The target customers of the company are healthcare providers, research institutions, and cosmetic companies.

The company generates revenue by providing anti-aging and anti-aging stem cell therapy products.

After the series A funding, the company will further deepen its independent research and development of mesenchymal stem cell exosome technology and promote technological breakthroughs and marketization of related products.

## Funding rounds

- Series A, Dec 14, 2024 — HY Capital, Shanghai Huamin Investment Management Co.,Ltd.

## Investors

- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series A
- Shanghai Huamin Investment Management Co.,Ltd. — Series A